Thyroid Eye Disease (TED) Clinical Trials

RECRUITING: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease.
https://clinicaltrials.gov/study/NCT06248619?term=NCT06248619&rank=1

TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.

FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.

Research presented  at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.

Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.

Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.

See “Understanding Thyroid Eye Disease” contributed by Immunovant.

Viridian is a biotechnology company based in Waltham, Massachusetts focused on discovering and developing potential new medicines for people living with autoimmune and rare diseases.

Leveraging our team’s expertise in antibody discovery, protein engineering, and clinical development, Viridian is studying multiple potential new treatment options in clinical trials for people living with thyroid eye disease (TED). All of Viridian’s TED clinical trials are fully enrolled, therefore no longer seeking additional participants. For more information on these clinical trials, please visit https://clinicaltrials.gov/search?lead=Viridian or speak with a healthcare provider.

Randomized, double-masked, placebo-controlled study to investigate the efficacy and safety of TOUR006 (pacibekitug) in adults with TED

Intervention:
TOUR006 (pacibekitug), a fully human monoclonal antibody against IL-6L
Delivery – subcutaneous injection

Total Number of injections – 3
Time between injections – 8 weeks

Recruiting – 81 participants
NCT Number: NCT06088979
Study Name: spiriTED

Visit: https://clinicaltrials.gov/study/NCT06088979 for more information.